It has the potential to be the next frontier in the psychedelics renaissance, and it represents an unprecedented opportunity to innovate a notable advancement in mental health therapy. In anecdotal studies, mescaline has shown promise in treating depression, anxiety, PTSD,...
Marc Davis
|
April 6, 2021
|
Fifty-three years after LSD was banned by the FDA, psychedelic drugs are making a comeback. Only instead of being the pills, mushrooms and acid tabs that helped college students to “turn on, tune in, drop out” Timothy Leary-style, today’...
Richard (Rick) Mills
|
December 3, 2019
|
Psychedelics are the real deal. They can help people in need, change the world, and make a lot of money, all at the same time. The severity of the opioid crisis has been well documented and needs a solution: One that is able to reduce the both the strain on thousands impa...
Omri Wallach
|
January 28, 2020
|
(Click image to play video.) A renewed interest in the therapeutic power psychedelic of compounds is revealing a potent and commercially viable solution. Vancouver BC-based Universal Ibogaine Inc. (UI) ( TSX-V: IBO , Forum ) is positioned to address the opioid e...
Dave Jackson
|
October 26, 2021
|
When Stockhouse Editorial last caught up with Toronto-based CYBIN Inc. ( N.CYBN , OTC: CYBN , Forum ) back in September 2020 , the psychedelic life sciences company was just going public…and to much fanfare. Cybin is a life sciences company that views psychedelic subst...
Dave Jackson
|
October 19, 2021
|
Numinus Wellness is in the business of psychedelic medicine but, more importantly, the mental health business. The mental health business is a sector that will be worth an estimated $530 billion dollars by the year 2030. Numinus has already seen more than a 618% ...
Brieanna McCutcheon
|
January 30, 2023
|
Universal Ibogaine Inc. (UI) ( TSX-V.IBO , Forum ) is a company uniquely-positioned to address the opioid epidemic through a safe, effective, and proven plant medicine – Ibogaine – and a proven treatment protocol which has successfully treated thousands of patients. ...
Dave Jackson
|
January 21, 2022
|
The compelling reasons behind those descriptors are explored in a Dawson James Securities report. In an Aug. 26 research note, analyst Jason Kolbert reported that DawsonJames Securities initiated coverage on Fortress Biotech Inc. (FBIO:NASDAQ) with a Buy rating and ...
Streetwise Reports
|
September 5, 2019
|
(Image via Numinus Wellness Inc.) In 2020, Health Canada began allowing select patients to take psilocybin for relief of end-of-life-distress. This was followed by a proposed regulation revision that could allow doctors to prescribe both psilocybin and MDMA for t...
Stockhouse Editorial
|
January 14, 2021
|
The case for investing in this company was made in an H.C. Wainwright & Co. report. In an April 22, 2019 research note, analyst Ram Selvaraju reported that H.C. Wainwright & Co. initiated coverage on Aquestive Therapeutics Inc. (AQST:NASDAQ) , "an undervalued spec...
Streetwise Reports
|
April 29, 2019
|